Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
3.850
-0.030 (-0.77%)
At close: Nov 20, 2024, 4:00 PM
3.912
+0.062 (1.61%)
After-hours: Nov 20, 2024, 5:04 PM EST
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 20 employees as of December 31, 2023. The number of employees increased by 3 or 17.65% compared to the previous year.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,061,150
Market Cap
230.00M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| TruBridge | 3,219 |
| Aurora Cannabis | 1,073 |
| Lifecore Biomedical | 524 |
| Pulmonx | 279 |
| LifeMD | 211 |
| Precigen | 202 |
| Biomea Fusion | 103 |
| aTyr Pharma | 59 |
ELDN News
- 8 days ago - Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewsWire
- 22 days ago - Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart - Seeking Alpha
- 23 days ago - Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 23 days ago - Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results - GlobeNewsWire
- 4 months ago - Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection - GlobeNewsWire